ArticleNAR genomics and bioinformatics2026
Eukan: a fully automated nuclear genome annotation pipeline for less studied and divergent eukaryotes.
Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we introduce a new annotation pipeline, called Eukan, designed to deliver reliably high-quality results across a broad range of eukaryotes. First, experimental evidence is automatically leveraged to refine predictions, specifically, RNA-Seq coverage to inform generalized Hidden Markov Model gene prediction and intron lengths to inform protein sequence alignments. Second, a consensus is created from an empirically optimized weighting of gene predictions from multiple sources. Third, Eukan runs a post-annotation routine to recover gene predictions missing from the consensus that otherwise have strong transcript support and appear to be protein-coding. We compare the results of Eukan with those of three popular freely available pipelines (Maker, Braker, and Gemoma) on 17 phylogenetically diverse haploid and diploid nuclear genomes. In addition to the commonly reported annotation accuracy statistics, we define a novel classification system of critical defects commonly observed in automated annotations. Furthermore, we demonstrate that each of the tested pipelines correctly identified the majority of the validated "gold standard" genes across the test set, but each pipeline uniquely generates a non-negligible portion of either fragmented, artificially fused, or missing genes. Despite that, Eukan performs consistently well where other pipelines encounter challenges, such as for compact protist genomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.